• 한국임상수의학회지
• /
• 제25권5호
• /
• pp.396-399
• /
• 2008

A 2-year-old intact female dachshund dog was presented with recurrent subcutaneous nodules and fistulations on the neck, back and hip. The patient was diagnosed as a sterile nodular panniculitis based on the cytology, histopathology, and cultures for bacteria and fungus. The fistulas were surgically removed and methylprednisolone was administrated 2 mg/kg twice daily per oral. The lesions were all disappeared, but the relapses were happened when the dosage of the drug was tapered off. The repeated treatments with methylprednisolone or azathioprine were performed, consequently, the patient was controlled with relatively low-dosage methylprednisolone (0.25 mg/kg, every third day).

• Journal of Veterinary Science
• /
• 제25권1호
• /
• pp.15.1-15.15
• /
• 2024

Background: The anti-programmed death 1 (PD-1) antibody has led to durable clinical responses in a wide variety of human tumors. We have previously developed the caninized anti-canine PD-1 antibody (ca-4F12-E6) and evaluated its therapeutic properties in dogs with advance-staged oral malignant melanoma (OMM), however, their therapeutic effects on other types of canine tumors remain unclear. Objective: The present clinical study was carried out to evaluate the safety profile and clinical efficacy of ca-4F12-E6 in dogs with advanced solid tumors except for OMM. Methods: Thirty-eight dogs with non-OMM solid tumors were enrolled prospectively and treated with ca-4F12-E6 at 3 mg/kg every 2 weeks of each 10-week treatment cycle. Adverse events (AEs) and treatment efficacy were graded based on the criteria established by the Veterinary Cooperative Oncology Group. Results: One dog was withdrawn, and thirty-seven dogs were evaluated for the safety and efficacy of ca-4F12-E6. Treatment-related AEs of any grade occurred in 13 out of 37 cases (35.1%). Two dogs with sterile nodular panniculitis and one with myasthenia gravis and hypothyroidism were suspected of immune-related AEs. In 30 out of 37 dogs that had target tumor lesions, the overall response and clinical benefit rates were 6.9% and 27.6%, respectively. The median progression-free survival and overall survival time were 70 days and 215 days, respectively. Conclusions: The present study demonstrated that ca-4F12-E6 was well-tolerated in non-OMM dogs, with a small number of cases showing objective responses. This provides evidence supporting large-scale clinical trials of anti-PD-1 antibody therapy in dogs.